CLARIVATE PLC (CLVT) Form 10-Q — Jul 29, 2026

$CLVTForm 10-QFiled Jul 29, 2026, 6:04 AM ET0001764046-26-000091Original filing

Clarivate reported a net loss of $308.8 million for the six months ended June 30, 2026, compared to a loss of $175.9 million in the prior year period, primarily due to a non-cash goodwill impairment charge of $221.7 million. The impairment was triggered by the anticipated sale price of the Life Sciences & Healthcare (LS&H) business, which the company announced is under a definitive agreement to be sold. Total revenue decreased 3.5% year-over-year to $1.17 billion, driven by product group wind-downs and lower transactional activity across all segments.

Key figures

Cash Position: 217.7
Adjusted EBITDA: 488.4
Shares Repurchased: 7
Goodwill Impairment: 221.7
Revenues LS&H Segment: 182

Price after filing

1 day: +12.7%7 days: -7.5%30 days: -4.7%

Close on the filing date to close N calendar days later (from $2.13). Historical, not a forecast.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.